These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 30286627)

  • 1. Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer.
    Reckamp K; Lin HM; Huang J; Proskorovsky I; Reichmann W; Krotneva S; Kerstein D; Huang H; Lee J
    Curr Med Res Opin; 2019 Apr; 35(4):569-576. PubMed ID: 30286627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls.
    Li J; Knoll S; Bocharova I; Tang W; Signorovitch J
    Curr Med Res Opin; 2019 Jan; 35(1):105-111. PubMed ID: 30362839
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    Kuo CS; Tung PH; Huang AC; Wang CC; Chang JW; Liu CY; Chung FT; Fang YF; Guo YK; Yang CT
    BMC Cancer; 2021 Mar; 21(1):309. PubMed ID: 33761908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
    Zhao M; Shao T; Shao H; Zhou C; Tang W
    BMC Cancer; 2024 Feb; 24(1):186. PubMed ID: 38331773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS; Araújo A; Zhang J; Signorovitch J; Zhou ZY; Cai X; Liu G
    J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
    Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
    JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
    Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
    Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.
    Hochmair M; Weinlinger C; Schwab S; Naber J; Setinek U; Krenbek D; Urban MH; Fabikan H; Watzka S; Koger R; Fazekas A; Bitterlich E; Valipour A; Burghuber OC
    Anticancer Drugs; 2019 Aug; 30(7):e0787. PubMed ID: 31305295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Kay S; Walton LJ; Shen J; Popat S; Camidge DR
    Curr Med Res Opin; 2022 Sep; 38(9):1587-1593. PubMed ID: 35815801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China.
    Luo X; Zhou Z; Zeng X; Peng L; Liu Q
    Front Public Health; 2022; 10():985834. PubMed ID: 36211665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
    Carlson JJ; Canestaro W; Ravelo A; Wong W
    J Med Econ; 2017 Jul; 20(7):671-677. PubMed ID: 28332433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
    Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
    Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparisons of brigatinib and alectinib for front-line
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
    Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis.
    Elliott J; Bai Z; Hsieh SC; Kelly SE; Chen L; Skidmore B; Yousef S; Zheng C; Stewart DJ; Wells GA
    PLoS One; 2020; 15(2):e0229179. PubMed ID: 32074131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Alectinib in Patients with
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
    Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.
    Lin JJ; Zhu VW; Schoenfeld AJ; Yeap BY; Saxena A; Ferris LA; Dagogo-Jack I; Farago AF; Taber A; Traynor A; Menon S; Gainor JF; Lennerz JK; Plodkowski AJ; Digumarthy SR; Ou SI; Shaw AT; Riely GJ
    J Thorac Oncol; 2018 Oct; 13(10):1530-1538. PubMed ID: 29935304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: A network meta-analysis.
    Fan J; Fong T; Xia Z; Zhang J; Luo P
    Cancer Med; 2018 Oct; 7(10):4993-5005. PubMed ID: 30230699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.